PDF(Pubmed)
Abstract：
A third mRNA vaccine booster is recommended to improve immunity against SARS-CoV-2 in kidney transplant recipients (KTRs). However, the immunity against SARS-CoV-2 Ancestral strain and Delta and Omicron variants elicited by the third dose of inactivated booster vaccine in KTRs remains unknown.
The blood parameters related to blood cells count, hepatic function, kidney function, heart injury and immunity were explored clinically from laboratory examinations. SARS-CoV-2 specific antibody IgG titer was detected using an enzyme-linked immunosorbent assay. Cellular immunity was analyzed using interferon-γ enzyme-linked immunospot assay.
The results showed that there were no severe adverse effects and apparent changes of clinical laboratory biomarkers in KTRs and healthy volunteers (HVs) after homologous inactivated vaccine booster. A third dose of inactivated vaccine booster significantly increased anti-Ancestral-spike-trimer-IgG and anti-Ancestral-receptor binding domain (RBD)-IgG titers in KTRs and HVs compared with the second vaccination. However, the anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG titers were significantly lower than anti-Ancestral-RBD-IgG titer in KTRs and HVs after the third dose. Notably, only 25.6% (10/39) and 10.3% (4/39) of KTRs had seropositivity for anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG after booster, which were significantly lower than HVs (anti-Delta-RBD-IgG: 100%, anti-Omicron-RBD-IgG: 77.8%). Ancestral strain nucleocapsid protein and spike specific T cell frequency after booster was not significantly increased in KTRs compared with the second dose, significantly lower than that in HVs. Moreover, 33.3% (12/36), 14.3% (3/21) and 14.3% (3/21) of KTRs were positive for the Ancestral strain and Delta and Omicron spike-specific T cells, which were significantly lower than HVs (Ancestral: 80.8%, Delta: 53.8%, and Omicron: 57.7%).
A third dose of inactivated booster vaccine may significantly increase humoral immunity against the Ancestral strain in KTRs, while humoral and cellular immunity against the Delta and Omicron variants were still poor in KTRs.
The blood parameters related to blood cells count, hepatic function, kidney function, heart injury and immunity were explored clinically from laboratory examinations. SARS-CoV-2 specific antibody IgG titer was detected using an enzyme-linked immunosorbent assay. Cellular immunity was analyzed using interferon-γ enzyme-linked immunospot assay.
The results showed that there were no severe adverse effects and apparent changes of clinical laboratory biomarkers in KTRs and healthy volunteers (HVs) after homologous inactivated vaccine booster. A third dose of inactivated vaccine booster significantly increased anti-Ancestral-spike-trimer-IgG and anti-Ancestral-receptor binding domain (RBD)-IgG titers in KTRs and HVs compared with the second vaccination. However, the anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG titers were significantly lower than anti-Ancestral-RBD-IgG titer in KTRs and HVs after the third dose. Notably, only 25.6% (10/39) and 10.3% (4/39) of KTRs had seropositivity for anti-Delta-RBD-IgG and anti-Omicron-RBD-IgG after booster, which were significantly lower than HVs (anti-Delta-RBD-IgG: 100%, anti-Omicron-RBD-IgG: 77.8%). Ancestral strain nucleocapsid protein and spike specific T cell frequency after booster was not significantly increased in KTRs compared with the second dose, significantly lower than that in HVs. Moreover, 33.3% (12/36), 14.3% (3/21) and 14.3% (3/21) of KTRs were positive for the Ancestral strain and Delta and Omicron spike-specific T cells, which were significantly lower than HVs (Ancestral: 80.8%, Delta: 53.8%, and Omicron: 57.7%).
A third dose of inactivated booster vaccine may significantly increase humoral immunity against the Ancestral strain in KTRs, while humoral and cellular immunity against the Delta and Omicron variants were still poor in KTRs.
摘要：
未经证实：建议使用第三种mRNA疫苗加强剂，以提高肾移植受者（KTRs）对SARS-CoV-2的免疫力。然而,在KTR中通过第三剂灭活加强疫苗引起的针对SARS-CoV-2祖先株以及Delta和Omicron变体的免疫力仍然未知。
未经鉴定：与血细胞计数有关的血液参数，肝功能,肾功能,从实验室检查中对心脏损伤和免疫力进行了临床研究。使用酶联免疫吸附测定法检测SARS-CoV-2特异性抗体IgG滴度。使用干扰素-γ酶联免疫斑点测定法分析细胞免疫。
UNASSIGNED：结果表明，同源灭活疫苗加强后，KTRs和健康志愿者（HVs）中没有严重的不良反应和临床实验室生物标志物的明显变化。与第二次疫苗接种相比，第三次剂量的灭活疫苗加强剂显着增加了KTR和HV中的抗祖先刺突三聚体IgG和抗祖先受体结合域（RBD）IgG滴度。然而,第三次给药后,KTRs和HV的抗Delta-RBD-IgG和抗Omicron-RBD-IgG滴度显著低于抗Ancestral-RBD-IgG滴度.值得注意的是,只有25.6％（10/39）和10.3％（4/39）的KTRs在加强后对抗Delta-RBD-IgG和抗Omicron-RBD-IgG具有血清阳性，显着低于HV（抗Delta-RBD-IgG：100％，抗Omicron-RBD-IgG：77.8%）。与第二剂量相比，加强后KTRs的祖先菌株核衣壳蛋白和尖峰特异性T细胞频率没有显着增加，明显低于HV。此外，33.3%（12/36），14.3％（3/21）和14.3％（3/21）的KTRs对祖先菌株和Delta和Omicron穗特异性T细胞呈阳性，显着低于HV（祖先：80.8%，三角洲：53.8%，和Omicron：57.7%）。
UNASSIGNED：第三剂灭活加强疫苗可能显着提高KTR中针对祖先菌株的体液免疫，而KTR中针对Delta和Omicron变体的体液和细胞免疫仍然较差。
未经鉴定：与血细胞计数有关的血液参数，肝功能,肾功能,从实验室检查中对心脏损伤和免疫力进行了临床研究。使用酶联免疫吸附测定法检测SARS-CoV-2特异性抗体IgG滴度。使用干扰素-γ酶联免疫斑点测定法分析细胞免疫。
UNASSIGNED：结果表明，同源灭活疫苗加强后，KTRs和健康志愿者（HVs）中没有严重的不良反应和临床实验室生物标志物的明显变化。与第二次疫苗接种相比，第三次剂量的灭活疫苗加强剂显着增加了KTR和HV中的抗祖先刺突三聚体IgG和抗祖先受体结合域（RBD）IgG滴度。然而,第三次给药后,KTRs和HV的抗Delta-RBD-IgG和抗Omicron-RBD-IgG滴度显著低于抗Ancestral-RBD-IgG滴度.值得注意的是,只有25.6％（10/39）和10.3％（4/39）的KTRs在加强后对抗Delta-RBD-IgG和抗Omicron-RBD-IgG具有血清阳性，显着低于HV（抗Delta-RBD-IgG：100％，抗Omicron-RBD-IgG：77.8%）。与第二剂量相比，加强后KTRs的祖先菌株核衣壳蛋白和尖峰特异性T细胞频率没有显着增加，明显低于HV。此外，33.3%（12/36），14.3％（3/21）和14.3％（3/21）的KTRs对祖先菌株和Delta和Omicron穗特异性T细胞呈阳性，显着低于HV（祖先：80.8%，三角洲：53.8%，和Omicron：57.7%）。
UNASSIGNED：第三剂灭活加强疫苗可能显着提高KTR中针对祖先菌株的体液免疫，而KTR中针对Delta和Omicron变体的体液和细胞免疫仍然较差。
